InvestorsHub Logo
Followers 19
Posts 334
Boards Moderated 0
Alias Born 07/25/2016

Re: dangerM post# 45555

Monday, 11/05/2018 10:44:47 PM

Monday, November 05, 2018 10:44:47 PM

Post# of 48316
I am also anticipating responses somewhere around 30% for the preliminary analysis. DVAX's BORR at 21.4% is probably the most promising at the moment for actual nonresponders (to anti-pd-1) with advanced melanoma. We'll see what tomorrow brings.

The phase 1 TNBC study was also only designed to detect immunological responses after a single cycle of treatment on TAVO. The fact that 2/2 patients who went straight on to anti-pd-1 treatment immediately after TAVO responded is very, very intriguing given that only 5% of TNBC patients ever respond to anti-pd-1 therapy.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News